In Brief: Whitehall-Robins' Orudis KT
This article was originally published in The Tan Sheet
Executive Summary
Whitehall-Robins' Orudis KT: FDA suggests company should "submit the blend uniformity and content uniformity validation data to the NDA reviewer at the Center for Drug Evaluation & Research for evaluation" in the event the company decides to resume production of the OTC NSAID at its Guayma, Puerto Rico manufacturing facility. FDA makes the suggestion in a Sept. 25 warning letter to the American Home Products firm. The warning letter follows a June 9-Aug. 11 inspection of the facility and FDA observations about out-of-spec lots and failure to have adequate acceptance criteria for testing of Orudis KT. As a result of the agency's FD 483 inspections report, Whitehall-Robins initiated a recall of one lot of the product Sept. 9...
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
People In Brief
Perrigo promotes in pricing, planning
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: